Armata Pharmaceuticals receives two U.S. patents for phage therapies

Wed, 07 Oct 2026 07:01:56 -0400

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that the U.S. Patent and Trademark Office has issued two patents covering its bacteriophage clinical candidates, AP-SA02 and AP-PA02, according to a company press release dated Oct. 7, 2026.

U.S. Patent No. 12,751,983, issued Oct. 6, 2026, covers methods of treating Staphylococcus aureus infections using AP-SA02, which is in development for the adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA. The patent is expected to provide protection until at least February 2041, with potential extensions.

U.S. Patent No. 12,594,312, issued April 7, 2026, covers methods of treating Pseudomonas infections using AP-PA02,

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Wed, 07 Oct 2026 07:00:00 -0400

Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041

LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Wed, 07 Oct 2026 07:00:00 -0400

Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041

Form 8-K Armata Pharmaceuticals, For: Sep 23

Wed, 23 Sep 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260923/27093270.html

Armata gets $3.7M from U.S. DoW for AP-SA02 Phase 3 program

Wed, 23 Sep 2026 07:01:15 -0400

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has received $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of its bacteriophage therapeutic AP-SA02, according to a company statement.

The funding is the first received specifically for Phase 3 execution under a previously announced Department of War award, managed through the Medical Technology Enterprise Consortium and the Naval Medical Research Command, with support from the Defense Health Agency and Joint Warfighter Medical Research Program. Combined with $28.7 million in prior funding, cumulative non-dilutive support for the AP-SA02 program now totals approximately $32.4 million.

AP-SA02 is being developed

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Wed, 23 Sep 2026 07:00:00 -0400

Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia

New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million

LOS ANGELES, Sept. 23, 2026 /PRNewswire/ --

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Wed, 23 Sep 2026 07:00:00 -0400

Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia

New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million

LOS ANGELES, Sept. 23, 2026 /PRNewswire/ --

H.C. Wainwright Reiterates Buy Rating on Armata Pharmaceuticals (ARMP)

Tue, 22 Sep 2026 07:36:23 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $15.00 price target on Armata Pharmaceuticals (NYSE: ARMP).

The analyst commented: "New data further characterize AP-SA02's controlled genomic diversity. Armata presented data at the 2026 International Symposium on Staphylococci and Staphylococcal Infections (ISSSI) further characterizing the controlled genomic diversity within AP-SA02, its investigational phage cocktail being developed as an adjunct treatment for complicated S. aureus bacteremia. Recall, the observation that the ARSA0002 component contains six sub-consensus genetic variants and that different variants can become enriched following exposure to different patient isolates had been previously disclosed. The ISSSI presentation builds on those

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Mon, 21 Sep 2026 07:00:00 -0400

Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots

Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20^th International Symposium on Staphylococci and Staphylococcal Infections

LOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Armata Pharmaceuticals,

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Mon, 21 Sep 2026 07:00:00 -0400

Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots

Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20^th International Symposium on Staphylococci and Staphylococcal Infections

LOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Armata Pharmaceuticals,

Form 8-K Armata Pharmaceuticals, For: Sep 14

Mon, 14 Sep 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260914/27055299.html

FDA grants Armata Pharmaceuticals breakthrough therapy status for AP-SA02

Mon, 14 Sep 2026 07:01:22 -0400

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AP-SA02, the company's intravenously administered bacteriophage product candidate for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA).

AP-SA02 now holds three FDA designations: Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP). Breakthrough Therapy designation is designed to expedite development and review of therapies for serious or life-threatening conditions that show preliminary clinical evidence of potential substantial improvement over available treatments.

The designation is supported by data from the Phase 1b/2a diSArm

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Mon, 14 Sep 2026 07:00:00 -0400

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies

Potentially accelerating the path to market for this innovative antibacterial treatment

AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Mon, 14 Sep 2026 07:00:00 -0400

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies

Potentially accelerating the path to market for this innovative antibacterial treatment

AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held in New York from September 14-16, 2026.

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:00:00 -0400

Armata Pharmaceuticals publishes phage biology study in molecular journal

Thu, 03 Sep 2026 07:01:02 -0400

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the publication of a peer-reviewed paper in the Journal of Molecular Biology examining the structural biology of a bacteriophage used in its clinical pipeline.

The paper, titled "Insights into Genome Ejection by a Therapeutic phiKMV-like Bacteriophage," presents a structural analysis of Ar-KM, a phage that targets Pseudomonas aeruginosa. Ar-KM is a component of Armata's AP-PA02 program, an inhaled bacteriophage candidate that has completed Phase 2 clinical studies in cystic fibrosis and non-CF bronchiectasis patients with chronic pulmonary P. aeruginosa infection.

Using cryo-electron microscopy, proteomics, and bioinformatics, researchers captured three distinct states of the phage particle

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Thu, 03 Sep 2026 07:00:00 -0400

LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Thu, 03 Sep 2026 07:00:00 -0400

Armata Pharmaceuticals, Inc. (ARMP) Tops Q2 EPS by 17c

Wed, 12 Aug 2026 16:47:22 -0400

Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q2 EPS of ($0.27), $0.17 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $2.51 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913299.html

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913299.html

Form 8-K Armata Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913141.html

Form 8-K Armata Pharmaceuticals, For: Aug 12

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913141.html

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.

StreetInsider.com News Articles

Armata Pharmaceuticals receives two U.S. patents for phage therapies

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Form 8-K Armata Pharmaceuticals, For: Sep 23

Armata gets $3.7M from U.S. DoW for AP-SA02 Phase 3 program

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

H.C. Wainwright Reiterates Buy Rating on Armata Pharmaceuticals (ARMP)

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Form 8-K Armata Pharmaceuticals, For: Sep 14

FDA grants Armata Pharmaceuticals breakthrough therapy status for AP-SA02

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals publishes phage biology study in molecular journal

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals, Inc. (ARMP) Tops Q2 EPS by 17c

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Form 10-Q Armata Pharmaceuticals, For: Jun 30

Form 8-K Armata Pharmaceuticals, For: Aug 12

Form 8-K Armata Pharmaceuticals, For: Aug 12

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update